Elanco Animal Health Incorporated · NYSE:ELAN
Elanco Animal Health — Merger or Acquisition (June 2021)
16 slides from Elanco Animal Health's merger presentation, Jun 16, 2021
Slide 1: Elanco Animal Health to Acquire KindredBio
Elanco Animal Health to Acquire June 16, 2021 Exhibit 99.2
Slide 2: Important Information
Important Information 2 Important Information for Investors and Stockholders This presentation does not constitute a solicitation of any vote or approval in connection with the proposed acquisition of K ind red Biosciences, Inc. (“ KindredBio ”) by Elanco Animal Health Incorporated (“Elanco” and suc
Slide 3: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward - Looking Statements 3 This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements included in this presentation that are not a descri
Slide 4: Well-Positioned for the Next Era of Pet Health Growth
4 Well - Positioned for the Next Era of Pet Health Growth Building a Global, Independent, Fit - for - Purpose Animal Health Leader
Slide 5: Accelerating Our Expansion in the Attractive Pet Health Market
Accelerating Our Expansion in the Attractive Pet Health Market 5 Market Expansion in the fast - growing $1B+ dermatology market , increasing pet owner options beyond today’s current therapies Portfolio Significant accretive revenue growth opportunity through a differentiated, disruptive portfolio wi
Slide 6: Amplified Innovation Expected Contribution to Revenue Growth
Amplified Innovation Expected Contribution to Revenue Growth 6 2021 2022 2023 2024 2025 $80 - $100 Pet Health Farm Animal $600 - $700 with KindredBio as outlined at Dec 2020 Investor Day Enriched probability of success in dermatology Peak Sales of Current KindredBio Pipeline Expected Well Beyond 202
Slide 7: Enhancing Our Long-Term Growth Algorithm
Enhancing Our Long - Term Growth Algorithm (1) Non - GAAP financial measure 7 Growth Profitability Targets Expected Results Today ~3% - 4% a verage a nnual r evenue g rowth 60% adj. g ross m argin (1) by 2023 and 31% adj. EBITDA margin (1) by 2024 Net l everage <3x by the end of 2023 Potential to ad
Slide 8: KindredBio at a Glance
KindredBio at a Glance 8 Company mission to bring to pets the same kinds of safe and effective medicines that humans enjoy Focused strategy to advance key molecule developments for established therapeutic targets through aggressive plans Exciting pipeline of high - value biologic candidates for dogs
Slide 9: Pet Therapeutics Market Tailwinds and Dynamics
Pet Therapeutics Market Tailwinds and Dynamics 9 Pets living longer with new care challenges Increased pet ownership Importance of companionship Owners spending more time with their pets Global runway for growth Omnichannel demand Role and incentives for veterinary practices Primarily private - pay
Slide 10: KindredBio Pipeline at a Glance
KindredBio Pipeline at a Glance Other product candidates in development (partial list) include KIND - bodies, VEGF antibody, and Checkpoint Inhibitors 10 Molecule Proposed Indication Preclinical Laboratory Pilot Studies Field Pilot Studies Pivotal Study Approval Partner Blockbuster Potential Canine
Slide 11: Dermatology Is a Large and Growing Market
Dermatology Is a Large and Growing Market 11 Canine atopic dermatitis (itching) is the leading reason owners take their dog to the veterinarian Atopic dermatitis is a large segment, with the leading two products selling approximately $1B annually We are pursuing a multi - pronged approach toward ato
Slide 12: Combined Dermatology Pipeline: Up to Four Launches by 2025
Combined Dermatology Pipeline: Up to Four Launches by 2025 Ilunicitinib JAK Inhibitor Oral JAK inhibitor with similar profile to market incumbent Pivotal studies underway in the U.S. and EU Initial technical section submissions targeted for late 2022 KIND - 039 integrates novel half - life extension
Slide 13: First-of-its-Kind Canine Parvovirus Therapy
First - of - its - Kind Canine Parvovirus Therapy 13 Highly Contagious Disease Disease Burden Cost Burden Affects mostly puppies, with no approved therapies Mortality rate as high as 91% if untreated; >60% of shelter dogs lack adequate titers to protect against parvo Supportive care can cost thousan
Slide 14: Canine Inflammatory Bowel Disease Therapy (Anti-TNF Antibody)
Canine Inflammatory Bowel Disease Therapy (Anti - TNF Antibody) 14 Disease Prevalence Disease Burden Cost Burden Recent Catalyst Majority of cases involve chronic states of diarrhea, vomiting, gastroenteritis, and other symptoms Diarrhea prevalence >5% Chronic condition, with diagnosis common in mid
Slide 15: Transaction Overview
Transaction Overview 15 Strategic Rationale • Increased exposure to the attractive, durable Pet Health market • Biologics (including mAbs ) as the future of veterinary medicine, with increased capabilities in R&D and manufacturing • Significantly expanded presence (up to four launches by 2025) in th
Slide 16: Building a Global, Independent, Fit-for-Purpose Animal Health Leader
Building a Global, Independent, Fit - for - Purpose Animal Health Leader 16 Today’s Takeaways Positioning for the next era of pet health growth through KindredBio’s additive pipeline including three potential blockbusters and Elanco’s global commercial capabilities Significantly enhances Elanco offe
Elanco Animal Health — Merger or Acquisition (June 2021) on 6ix